Universal Scientific Industrial (Shanghai) (601231) Q3 2026 earnings summary

Executive summary

• Q3 revenue was RMB 19.54bn, up 18.97% YoY; attributable net income reached RMB 714.6m, up 14.30% YoY.

• 9M revenue was RMB 46.88bn, up 7.42%; attributable net income was RMB 1.537bn, up 21.65%.

Financial highlights

• Q3 adjusted for non-recurring items, attributable net income was RMB 662.7m, up 19.94% YoY; 9M adjusted net income was RMB 1.452bn, up 28.38%.

• 9M operating profit was RMB 1.740bn, compared with RMB 1.466bn in the prior-year period; total profit was RMB 1.736bn.

• 9M net income was RMB 1.535bn; basic and diluted EPS were both RMB 0.65, versus RMB 0.58 and RMB 0.57, respectively, in 9M 2025.

Outlook and guidance

• Q4 revenue target: 15%–20% YoY growth, supported by higher key-material prices passed through and increased shipments in some businesses.

• Q4 operating margin expected to decline ~1.8 percentage points YoY, reflecting last year's land-disposal gain comparison and a higher materials cost share.

• Targets depend on stable international trade conditions, healthy EMS industry conditions, market development and order execution; actual results remain uncertain.